What question did this study set out to answer?

The aim is to evaluate pharmacotherapeutic strategies for managing 21-hydroxylase deficiency in congenital adrenal hyperplasia.

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia

View Full Paper

Ask AI

Bookmark

Authors

Review discusses pharmacotherapeutic approaches to control adrenal androgen in congenital adrenal hyperplasia, suggesting new treatment modalities.

The aim is to evaluate pharmacotherapeutic strategies for managing 21-hydroxylase deficiency in congenital adrenal hyperplasia.
Conducted a review of literature through PubMed up to April 2026.
Assessed evolving glucocorticoid formulations and non-glucocorticoid therapies.
Highlighted combination therapies and gene therapies targeting CYP21A2.
Glucocorticoids remain essential but pose dose-dependent risks.
Emerging therapies include CRF1 receptor and MC2R antagonists to reduce androgen levels.
Future strategies may involve upstream targeting of the hypothalamic-pituitary-adrenal axis.

Goai et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Review discusses pharmacotherapeutic approaches to control adrenal androgen in congenital adrenal hyperplasia, suggesting new treatment modalities.